太景醫藥研發控股股份有限公司
太景醫藥研發控股股份有限公司為新藥研發廠商,專注於治療具高度抗藥性之細菌感染與病毒性疾病。主要產品包括抗生素「太捷信(奈諾沙星)」及抗流感與抗 C 肝等臨床開發中藥物。公司成立於 2001 年,總部位於台灣台北。
該股 RSI(6) 為 64.4,處於中性區間,短線無明顯超買超賣訊號。股價站上5日、20日均線,跌破60日、120日均線。KD 指標中性(K=76.5);MACD 柱狀體為正值,維持多方動能。 (自動產生 · 非投資建議)
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 08-10 | +117 | 0 | +2 | +118 |
| 08-07 | +229 | 0 | 0 | +229 |
| 08-06 | -81 | 0 | +2 | -80 |
| 08-05 | -110 | 0 | +10 | -110 |
| 08-04 | +189 | 0 | 0 | +189 |
| 08-03 | -64 | 0 | +2 | -64 |
| 07-31 | +117 | 0 | 0 | +117 |
| 07-30 | +170 | 0 | +18 | +170 |
| 07-29 | +160 | 0 | +34 | +160 |
| 07-28 | -7 | 0 | +18 | -8 |
| 07-27 | +12 | 0 | +2 | +13 |
| 07-24 | -53 | 0 | +16 | -52 |
| 07-23 | -205 | 0 | +8 | -206 |
| 07-22 | +340 | 0 | +2 | +340 |
| 07-21 | -70 | 0 | 0 | -70 |
| 07-20 | +294 | 0 | +12 | +293 |
| 07-17 | -299 | 0 | +20 | -299 |
| 07-16 | -3 | 0 | +2 | -3 |
| 07-15 | +43 | 0 | +2 | +42 |
| 07-14 | +86 | 0 | +25 | +87 |
| 07-13 | -199 | 0 | +18 | -199 |
| 07-09 | +29 | 0 | +2 | +29 |
| 07-08 | +22 | 0 | +2 | +22 |
| 07-07 | +254 | 0 | +10 | +254 |
| 07-06 | -330 | 0 | +9 | -330 |
| 07-03 | -348 | 0 | +14 | -348 |
| 07-02 | -285 | 0 | +4 | -285 |
| 07-01 | +197 | 0 | +6 | +195 |
| 06-30 | -84 | 0 | +3 | -82 |
| 06-29 | +341 | 0 | +3 | +341 |
| 06-26 | -299 | 0 | +26 | -304 |
| 06-25 | -55 | 0 | +7 | -55 |
| 06-24 | +730 | 0 | +8 | +729 |
| 06-23 | +31 | 0 | +22 | +25 |
| 06-22 | -263 | 0 | +30 | -267 |
| 06-18 | +42 | 0 | +2 | +39 |
| 06-17 | +6 | 0 | +6 | +5 |
| 06-16 | -392 | 0 | +2 | -404 |
| 06-15 | -48 | 0 | +9 | -50 |
| 06-12 | +466 | 0 | +10 | +465 |
| 06-11 | -74 | 0 | +6 | -74 |
| 06-10 | +56 | 0 | +5 | +42 |
| 06-09 | -589 | 0 | +14 | -589 |
| 06-08 | -564 | 0 | +112 | -515 |
| 06-05 | -607 | 0 | +12 | -609 |
| 06-04 | +530 | 0 | +4 | +529 |
| 06-03 | +497 | 0 | +6 | +494 |
| 06-02 | -310 | 0 | +13 | -310 |
| 06-01 | -350 | 0 | +2 | -350 |
| 05-29 | +469 | 0 | +6 | +471 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/04 | 228 萬 | +57.6% | -37.8% |
| 2026/03 | 145 萬 | -49.3% | -55.9% |
| 2026/02 | 285 萬 | -52.7% | -15.5% |
| 2026/01 | 604 萬 | -97.3% | +43.0% |
| 2025/12 | 2.24 億 | +5327.1% | +6482.8% |
| 2025/11 | 412 萬 | +25.9% | +30.8% |
| 2025/10 | 328 萬 | +225.4% | -16.7% |
| 2025/09 | 101 萬 | -61.1% | -66.5% |
| 2025/08 | 259 萬 | -15.8% | -17.1% |
| 2025/07 | 308 萬 | -5.4% | +24.0% |
| 2025/06 | 325 萬 | -14.0% | +51.9% |
| 2025/05 | 378 萬 | - | -96.7% |